

EQA round: BM2/23 - Bone Markers

Deadline: 27.10.2023

Setup: groups - manufacturer of kit; Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVPG = consensus of the participants' groups	LL = lower limit
CV = coefficient of variation	U _{AV} = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N _{tot} = total number of the results		N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]	
							AV	U _{AV}	D _{max}	LL	UL				
(435) 25-hydroxyvitamin D	[nmol/L]				29							27	25	93	
Sample A		133	20	15	29							27	26	96	
(1) Abbott		125	3,6	2,9	6	0	CVPG	127	2,4	33%	85	169	6		
(60) Roche		132	19	15	17	0	CVPG	138	3,4	33%	92,4	184	17		
Other					6	0							4		
								2x 12, 1x 73, 2x 179, 1x 998							
Sample B		71,1	14	19	29							27	25	93	
(1) Abbott		62,7	2,5	4	6	0	CVPG	63,4	1,3	33%	42,4	84,4	6		
(60) Roche		71	12	17	17	0	CVPG	73,7	2,6	33%	49,3	98,1	17		
Other					6	0							4		
								2x 12, 1x 73, 2x 179, 1x 998							
(434) Osteocalcin	[µg/L]				18							16	14	88	
Sample A		94,4	8,7	9,2	18							16	14	88	
(60) Roche		94,6	7	7,4	16	0	CVPG	96	1,5	13%	83,5	109	16		
Other					2	0							0		
								1x 73, 1x 164							
Sample B		17,8	1,2	6,6	18							16	15	94	
(60) Roche		17,8	0,93	5,2	16	0	CVPG	18	0,23	13%	15,6	20,4	16		
Other					2	0							0		
								1x 73, 1x 164							
(433) P1NP	[µg/L]				13							13	13	100	
Sample A		168	13	7,6	13							13	13	100	
(60) Roche		166	10	6,2	12	0	CVPG	167	3,9	20%	133	201	12		
Other					1	0							1		
								1x 73							
Sample B		25,8	2,4	9,2	13							13	13	100	
(60) Roche		25,5	2,1	8,4	12	0	CVPG	25,3	0,82	20%	20,2	30,4	12		
Other					1	0							1		
								1x 73							
(431) Parathyrin intact (PTH)	[pmol/L]				28							25	24	96	
Sample A		24,8	8,3	34	28							25	24	96	
(1) Abbott		37,3	0,8	2,1	5	0	CVPG	39,1	2	23%	30,1	48,1	5		
(60) Roche		21,3	1,8	8,3	15	0	CVPG	21	0,63	23%	16,1	25,9	15		
Other					8	0							5		
								1x 9, 2x 12, 1x 29, 1x 73, 3x 179							
Sample B		7,32	2,2	30	28							25	25	100	
(1) Abbott		11,6	0,51	4,4	5	0	CVPG	11,7	0,81	23%	9	14,4	5		
(60) Roche		6,27	0,56	8,9	15	0	CVPG	6,15	0,19	23%	4,73	7,57	15		
Other					8	1							5		
								1x 9, 2x 12, 1x 29, 1x 73, 3x 179							
(432) Collagen telopeptide CTx-β	[ng/L]				20							20	18	90	
Sample A		765	87	11	20							20	19	95	
(60) Roche		772	80	10	19	0	CVPG	772	18	17%	640	904	19		
Other					1	0							1		
								1x 73							
Sample B		292	21	7,1	20							20	18	90	
(60) Roche		294	19	6,4	19	0	CVPG	300	5,5	17%	249	351	19		
Other					1	0							1		
								1x 73							